{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreic5fiovogk5yn6clusqw6kp46llro6wtfxpwkcz4ycsu2ehake53q",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mmh437wn63b2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiajyzwqwbn4foqydui5u77akb4dela5sn3sxa5dclo6habrdal4uy"
    },
    "mimeType": "image/jpeg",
    "size": 516555
  },
  "path": "/news/2026-05-ozempic-glp-ras-cancers.html",
  "publishedAt": "2026-05-22T08:20:03.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "Real-world data show that GLP-1 receptor agonists (GLP-1s) may reduce metastatic progression of certain obesity-related cancers, namely lung, breast, colorectal, and liver cancers. In addition, GLP-1 receptor (GLP-1R) expression was associated with overall survival, suggesting that GLP-1 signaling could be involved in the progression of these cancers.",
  "title": "Ozempic and other GLP-1 RAs could slow progression of some cancers, data suggest"
}